|
10/15/2010 05:00 PM
|
|
Robot To Have First Clinical Trial Test In Prostate Cancer Patients
|
In the first-of-a-kind clinical trial, a robot will be used to place therapeutic radioactive seeds in prostate cancer patients. The National Cancer Institute-supported study, which will enroll 14 patients, has just opened at Thomas Jefferson University Hospital...
|
|
10/15/2010 04:00 PM
|
|
Urine Test For Prostate Cancer Hopeful
|
New research led by UK scientists has shown that a protein in urine could be a reliable marker for prostate cancer risk, alnd although there is still a lot of work to be done to move it from the laboratory to the clinic, the finding is raising hopes that an easy and reliable clinical test for prostate cancer is now much closer...
|
|
10/15/2010 02:00 PM
|
|
Prostate Cancer Advocates Circulate Petition To The NFL
|
As NFL stadiums and players turn pink this month in honor of National Breast Cancer Awareness Month, prostate cancer advocates salute the pink effort and are asking the NFL for equal opportunity awareness time for prostate cancer, a disease that currently affects 2.5 million American men...
|
|
10/14/2010 02:00 PM
|
|
Links Between XMRV And Human Disease Examined In New Studies
|
Evidence Supports Possible Links with Cancer but not Chronic Fatigue Syndrome Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease...
|
|
10/13/2010 02:00 PM
|
|
Abiraterone Acetate Improves Survival In Metastatic Castration-Resistant Prostate Cancer
|
Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm...
|
|
10/12/2010 05:00 PM
|
|
Prostate Cancer: Industrial-Academic Partnership To Help Urologists Zero In On Cancerous Tissue During Ultrasound-guided Biopsies, Localized Treatment
|
The National Institutes of Health has awarded a $3.3 million grant to a research team that includes Rutgers University to increase the reliability of imaging prostate cancer...
|
|
10/12/2010 03:00 PM
|
|
Calypso Medical Receives FDA 510(k) Clearance For Dynamic Edge Gating Technology
|
Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumors, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Calypso® System with Dynamic Edge™ Gating Technology...
|
|
10/12/2010 02:00 PM
|
|
More Than Half Of Men Dying Of Prostate Cancer Use Hospice Care But Most Wait Too Long To Enroll To Optimize The Benefits
|
More than half of men dying of prostate cancer use hospice care - a significant increase over the last two decades - but most wait too long to enroll so they can't take full advantage of the palliative care that could make their deaths easier, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center found...
|
|
10/12/2010 12:00 AM
|
|
Common Prostate Cancer Treatment Linked To Bone Decay
|
A common treatment for prostate cancer known as androgen deprivation therapy (ADT) is linked to bone decay, according to new research from the University of Melbourne in Australia...
|
|
10/11/2010 11:00 PM
|
|
New Advanced Prostate Cancer Drug, Abiraterone Acetate Extends Survival Time
|
An investigational drug aimed at treating patients with advanced prostate cancer was found to be so successful at extending survival times during a Phase III trial that it was unblinded, meaning that those on a placebo were offered the option of receiving abiraterone acetate, researchers from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust announced ...
|
|
10/11/2010 07:00 PM
|
|
New Study Shows Promise For Detecting Prostate Cancer
|
Prostate cancer -- the most common cancer afflicting American men -- may be effectively diagnosed at an early stage without ionizing radiation, using a non-invasive imaging technique known as contrast-enhanced ultrasound (CEUS), according to a report announced late last week at the 25th Annual Advances in Contrast Ultrasound - ICUS Bubble Conference in Chicago...
|
|
10/11/2010 06:00 PM
|
|
Abiraterone Phase III Clinical Trial Data To Be Highlight Of ESMO Meeting
|
Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer...
|
|
10/08/2010 07:00 PM
|
|
Vanderbilt Wins CHOICE Award For Prostate Cancer Research
|
Vanderbilt-Ingram Cancer Center has received a $7.6 million American Recovery and Reinvestment Act of 2009 (ARRA) stimulus grant to coordinate a study comparing the effectiveness of various treatments for prostate cancer. David Penson, M.D., M.P.H...
|
|
10/07/2010 04:00 PM
|
|
Popular Prostate Cancer Treatment Associated With Bone Decay
|
Using novel technology allowing "virtual bone biopsies" researchers have found that a common treatment for prostate cancer called androgen deprivation therapy (ADT) is associated with structural decay of cortical and trabecular bone. The study has been accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM)...
|
|
10/07/2010 03:00 PM
|
|
Half Of Irish Men Would Not Recognise The Symptoms Of Testicular Or Prostate Cancer, According To New Research By QUINN-healthcare
|
Half of Irish men said they would not recognise or be able to identify symptoms of testicular or prostate cancer, according to new research by QUINN-healthcare. Older men were more likely to be aware of how to identify symptoms (62% of men aged 55+ and 59% of men aged 45-54)...
|
